Fiduciary Financial Group LLC Has $275,000 Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Fiduciary Financial Group LLC lowered its stake in Bristol-Myers Squibb (NYSE:BMY) by 5.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,503 shares of the biopharmaceutical company’s stock after selling 269 shares during the quarter. Fiduciary Financial Group LLC’s holdings in Bristol-Myers Squibb were worth $275,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Wealthspire Advisors LLC grew its stake in Bristol-Myers Squibb by 0.6% in the 4th quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company’s stock valued at $1,622,000 after buying an additional 170 shares in the last quarter. Edmp Inc. grew its stake in Bristol-Myers Squibb by 0.4% in the 4th quarter. Edmp Inc. now owns 41,599 shares of the biopharmaceutical company’s stock valued at $2,353,000 after buying an additional 171 shares in the last quarter. Bedel Financial Consulting Inc. grew its stake in Bristol-Myers Squibb by 3.2% in the 4th quarter. Bedel Financial Consulting Inc. now owns 5,690 shares of the biopharmaceutical company’s stock valued at $340,000 after buying an additional 175 shares in the last quarter. King Wealth Management Group grew its stake in Bristol-Myers Squibb by 2.6% in the 4th quarter. King Wealth Management Group now owns 7,294 shares of the biopharmaceutical company’s stock valued at $413,000 after buying an additional 182 shares in the last quarter. Finally, Signet Investment Advisory Group Inc. grew its stake in Bristol-Myers Squibb by 2.3% in the 4th quarter. Signet Investment Advisory Group Inc. now owns 8,261 shares of the biopharmaceutical company’s stock valued at $467,000 after buying an additional 189 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on BMY. Wall Street Zen lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Friday, June 6th. Piper Sandler began coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $65.00 price target for the company. Jefferies Financial Group reduced their price target on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a research report on Wednesday, April 23rd. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Friday, April 25th. Finally, Argus upgraded shares of Bristol-Myers Squibb to a “hold” rating in a research report on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $58.00.

Bristol-Myers Squibb Stock Performance

Bristol-Myers Squibb stock opened at $49.96 on Wednesday. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The company has a market capitalization of $101.66 billion, a PE ratio of -11.30, a P/E/G ratio of 2.07 and a beta of 0.38. The firm has a fifty day simple moving average of $48.97 and a two-hundred day simple moving average of $54.92. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.50 by $0.30. The firm had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company’s quarterly revenue was down 5.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($4.40) earnings per share. Research analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Insider Activity

In other news, EVP Samit Hirawat acquired 4,250 shares of the stock in a transaction dated Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the purchase, the executive vice president now owns 83,513 shares in the company, valued at approximately $3,973,548.54. The trade was a 5.36% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.